SE459471B - Liposomal aerosolkomposition samt foerfarande och foerpackning foer framstaellning daerav - Google Patents
Liposomal aerosolkomposition samt foerfarande och foerpackning foer framstaellning daeravInfo
- Publication number
- SE459471B SE459471B SE8404118A SE8404118A SE459471B SE 459471 B SE459471 B SE 459471B SE 8404118 A SE8404118 A SE 8404118A SE 8404118 A SE8404118 A SE 8404118A SE 459471 B SE459471 B SE 459471B
- Authority
- SE
- Sweden
- Prior art keywords
- component
- chamber
- components
- mixing chamber
- aerosol
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims description 78
- 239000000203 mixture Substances 0.000 title claims description 58
- 238000000034 method Methods 0.000 title claims description 55
- 238000004806 packaging method and process Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 15
- 239000002502 liposome Substances 0.000 claims description 64
- 238000002156 mixing Methods 0.000 claims description 58
- 239000000463 material Substances 0.000 claims description 52
- 239000011149 active material Substances 0.000 claims description 46
- 239000007921 spray Substances 0.000 claims description 43
- 239000003380 propellant Substances 0.000 claims description 39
- 150000002632 lipids Chemical class 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 12
- 150000003904 phospholipids Chemical group 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000000446 fuel Substances 0.000 claims description 7
- 239000003981 vehicle Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940124630 bronchodilator Drugs 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 230000001088 anti-asthma Effects 0.000 claims description 3
- 239000000924 antiasthmatic agent Substances 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 3
- 239000012042 active reagent Substances 0.000 claims description 2
- 239000003263 anabolic agent Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000003433 contraceptive agent Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940124558 contraceptive agent Drugs 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 70
- 235000019441 ethanol Nutrition 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 30
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 20
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 19
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 19
- 239000008344 egg yolk phospholipid Substances 0.000 description 19
- 239000011521 glass Substances 0.000 description 19
- 229960000912 stanozolol Drugs 0.000 description 17
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 15
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
- 238000010276 construction Methods 0.000 description 11
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 10
- 239000000787 lecithin Substances 0.000 description 10
- 229940067606 lecithin Drugs 0.000 description 10
- 235000010445 lecithin Nutrition 0.000 description 10
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 9
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000008367 deionised water Substances 0.000 description 8
- 229910021641 deionized water Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 229960000585 bitolterol mesylate Drugs 0.000 description 7
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 description 7
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 7
- 229940093541 dicetylphosphate Drugs 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 6
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 6
- 239000011609 ammonium molybdate Substances 0.000 description 6
- 229940010552 ammonium molybdate Drugs 0.000 description 6
- 235000018660 ammonium molybdate Nutrition 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 229960002052 salbutamol Drugs 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229960002537 betamethasone Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- -1 vaccines Substances 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960004620 bitolterol Drugs 0.000 description 2
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- KILNVBDSWZSGLL-UHFFFAOYSA-N colfosceril palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940047135 glycate Drugs 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- ZUVCYFMOHFTGDM-UHFFFAOYSA-N hexadecyl dihydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(O)=O ZUVCYFMOHFTGDM-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 231100001228 moderately toxic Toxicity 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- QVGLHVDBDYLFON-UHFFFAOYSA-M sodium;1,3-dimethylpurin-7-ide-2,6-dione Chemical compound [Na+].O=C1N(C)C(=O)N(C)C2=C1[N-]C=N2 QVGLHVDBDYLFON-UHFFFAOYSA-M 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB838322178A GB8322178D0 (en) | 1983-08-17 | 1983-08-17 | Preparing aerosol compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8404118D0 SE8404118D0 (sv) | 1984-08-16 |
| SE8404118L SE8404118L (sv) | 1985-02-18 |
| SE459471B true SE459471B (sv) | 1989-07-10 |
Family
ID=10547457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8404118A SE459471B (sv) | 1983-08-17 | 1984-08-16 | Liposomal aerosolkomposition samt foerfarande och foerpackning foer framstaellning daerav |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS6089414A (en, 2012) |
| KR (1) | KR850001689A (en, 2012) |
| AT (1) | AT389993B (en, 2012) |
| AU (1) | AU569314B2 (en, 2012) |
| BE (1) | BE900375A (en, 2012) |
| CH (1) | CH667384B (en, 2012) |
| DE (1) | DE3430385A1 (en, 2012) |
| DK (1) | DK163479C (en, 2012) |
| ES (1) | ES535163A0 (en, 2012) |
| FI (1) | FI85214C (en, 2012) |
| FR (1) | FR2550706B1 (en, 2012) |
| GB (2) | GB8322178D0 (en, 2012) |
| GR (1) | GR80127B (en, 2012) |
| IE (1) | IE57537B1 (en, 2012) |
| IL (1) | IL72590A (en, 2012) |
| IT (1) | IT1175612B (en, 2012) |
| LU (1) | LU85512A1 (en, 2012) |
| NL (1) | NL8402514A (en, 2012) |
| NZ (1) | NZ209112A (en, 2012) |
| PT (1) | PT79104B (en, 2012) |
| SE (1) | SE459471B (en, 2012) |
| ZA (1) | ZA846064B (en, 2012) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3585967D1 (de) * | 1984-03-08 | 1992-06-11 | Phares Pharma Holland | Liposombildende zusammensetzung. |
| GB8423436D0 (en) * | 1984-09-17 | 1984-10-24 | Riker Laboratories Inc | Preparation of liposomes |
| CA1260393A (en) * | 1984-10-16 | 1989-09-26 | Lajos Tarcsay | Liposomes of synthetic lipids |
| GB8502892D0 (en) * | 1985-02-05 | 1985-03-06 | Sterwin Ag | Aerosol composition |
| WO1986006959A1 (en) * | 1985-05-22 | 1986-12-04 | Liposome Technology, Inc. | Liposome inhalation method and system |
| US5192528A (en) | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
| US5340587A (en) * | 1985-05-22 | 1994-08-23 | Liposome Technology, Inc. | Liposome/bronchodilator method & System |
| GB8522964D0 (en) * | 1985-09-17 | 1985-10-23 | Biocompatibles Ltd | Aerosol |
| JPS62270531A (ja) * | 1985-11-01 | 1987-11-24 | サントル ナシヨナ−ル ド ラ ルシエルシユ シヤンテイフイ−ク（セ−・エン・エル・エス） | 生体内でのイメ−ジング及び治療用の新規エアロゾル組成物 |
| IE63869B1 (en) * | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| US4897256A (en) * | 1986-11-25 | 1990-01-30 | Abbott Laboratories | LHRH analog formulations |
| US5030442A (en) * | 1987-03-30 | 1991-07-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition |
| US4828837A (en) * | 1987-03-30 | 1989-05-09 | Liposome Technology, Inc. | Non-crystalline minoxidil composition, its production and application |
| JP2581920B2 (ja) * | 1987-05-18 | 1997-02-19 | 有限会社野々川商事 | 化粧料 |
| FR2638639A1 (fr) * | 1988-11-08 | 1990-05-11 | Parincos Parfumerie Cosmet Int | Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique |
| JPH03193714A (ja) * | 1989-12-25 | 1991-08-23 | Kobayashi Kose Co Ltd | エアゾール型化粧料 |
| DE4203306A1 (de) * | 1992-02-06 | 1993-08-12 | Ig Spruehtechnik Gmbh | Asthma oder pulmonal-aerosolzubereitungen mit lecithin |
| ATE166573T1 (de) * | 1993-03-24 | 1998-06-15 | Ciba Geigy Ag | Verfahren zur herstellung einer liposomendispersion im hochdruckbereich |
| AU689786B2 (en) * | 1993-06-30 | 1998-04-09 | Genentech Inc. | Method for preparing liposomes |
| GB9409763D0 (en) * | 1994-05-16 | 1994-07-06 | Phares Pharma Holland | Liposome forming compositions |
| ES2111488B1 (es) * | 1996-01-17 | 1998-11-01 | Lucas Meyer S A | Utilizacion de composiciones proliposomas en la tintura, blanqueo y suavizado de la industrial textil y procedimiento para la preparacion de banos de tintura a partir de dichas composiciones proliposomas. |
| EP1013269A4 (en) * | 1997-06-06 | 2002-02-20 | Shionogi & Co | IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM |
| WO2000000178A1 (fr) * | 1998-06-30 | 2000-01-06 | Rohto Pharmaceutical Co., Ltd. | Compositions contenant des liposomes et/ou des emulsions et leur procede de preparation |
| EP1839648A3 (en) * | 1998-11-12 | 2007-11-21 | Transave, Inc. | An inhalation system |
| EP1128813B1 (en) * | 1998-11-12 | 2007-02-14 | Inc. Transave | An inhalation system |
| US7879351B2 (en) | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| ES2539591T3 (es) | 2002-10-29 | 2015-07-02 | Insmed Incorporated | Liberación sostenida de antiinfectantes |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| EP1954243A2 (en) * | 2005-10-26 | 2008-08-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method for preparing liposomes and uses thereof |
| ES2798263T3 (es) | 2005-12-08 | 2020-12-10 | Insmed Inc | Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares |
| JPWO2007117024A1 (ja) * | 2006-04-11 | 2009-08-20 | 株式会社ウイングターフ | ガス処理方法 |
| WO2008137717A1 (en) | 2007-05-04 | 2008-11-13 | Transave, Inc. | Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof |
| US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
| US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| CN102307557B (zh) * | 2008-12-29 | 2014-10-22 | 叶夫根尼·彼得罗维奇·格列比翁尼科夫 | 脂质体药物的制备方法和脂质体制备装置 |
| RU2470624C1 (ru) * | 2011-08-25 | 2012-12-27 | Евгений Петрович Гребенников | Устройство для получения липосомальных препаратов |
| ES2905368T3 (es) | 2012-05-21 | 2022-04-08 | Insmed Inc | Sistemas para el tratamiento de infecciones pulmonares |
| WO2014085526A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
| EP3104854B1 (en) | 2014-02-10 | 2020-04-08 | Respivant Sciences GmbH | Mast cell stabilizers for lung disease treatment |
| WO2015120389A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| ES2755941T3 (es) | 2014-05-15 | 2020-04-24 | Insmed Inc | Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| JP2019528320A (ja) | 2016-08-31 | 2019-10-10 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 |
| EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYNE-BASED COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS |
| JP7008975B2 (ja) * | 2017-08-31 | 2022-01-25 | クラシエホームプロダクツ株式会社 | 皮膚化粧料 |
| WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| JP7269378B2 (ja) * | 2020-07-17 | 2023-05-08 | ケーティー アンド ジー コーポレイション | エアロゾル生成物品用加圧装置及びそれを含むエアロゾル生成システム |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB780885A (en) * | 1955-05-03 | 1957-08-07 | Innoxa England Ltd | Foundation cream |
| GB993702A (en) * | 1961-11-10 | 1965-06-02 | Takeda Chemical Industries Ltd | An aerosol dispersing agent |
| DE1277210B (de) * | 1965-09-24 | 1968-09-12 | Revlon | Selbsttreibende Gemische |
| US3326416A (en) * | 1966-01-14 | 1967-06-20 | Du Pont | Apparatus for codispensing a plurality of liquids |
| US3325056A (en) * | 1966-02-23 | 1967-06-13 | Du Pont | Apparatus for codispensing a plurality of liquids |
| US3338479A (en) * | 1966-04-04 | 1967-08-29 | Leonard L Marraffino | Mixing head with secondary fluid adapted for connection with discharge means of primary fluid container |
| GB1287470A (en) * | 1968-11-25 | 1972-08-31 | Gillette Co | Pressurised dispensing package |
| US3594476A (en) * | 1969-05-12 | 1971-07-20 | Massachusetts Inst Technology | Submicron aqueous aerosols containing lecithin |
| NL7012832A (en, 2012) * | 1970-08-29 | 1972-03-02 | ||
| US3637114A (en) * | 1970-09-03 | 1972-01-25 | Philip Meshberg | Device for codispensing two materials |
| GB1372721A (en) * | 1971-01-16 | 1974-11-06 | Wilkinson Sword Ltd | Containers of antiseptics for the treatment of burns and scalds |
| DE2115926C3 (de) * | 1971-04-01 | 1978-05-03 | C.H. Boehringer Sohn, 6507 Ingelheim | 1 -(4-Hydroxy-3-dimethylaminosuIfamidophenyI)-2-aminoäthanderivate, Verfahren zu ihrer Herstellung und diese enthaltende Mittel |
| US3997467A (en) * | 1971-11-26 | 1976-12-14 | Pharmacia Aktiebolag | Foam forming composition |
| DE2346730C3 (de) * | 1973-09-17 | 1980-10-16 | Carl Heyer Gmbh, Inhalationstechnik, 5427 Bad Ems | Einrichtung zur Aerosolbehandlung von Menschen, Tieren, Gegenständen, Stoffen u.dgl. in einem Behandlungsraum |
| LU70720A1 (en, 2012) * | 1974-08-12 | 1976-08-19 | ||
| US4073412A (en) * | 1976-06-03 | 1978-02-14 | Blue Cross Laboratories, Inc. | Emulsified cookware lubricant having freeze-thaw stability |
| GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
| GB2001334B (en) * | 1977-07-19 | 1982-03-03 | Fisons Ltd | Pressurised aerosol formulation |
| FR2416008A1 (fr) * | 1978-02-02 | 1979-08-31 | Oreal | Lyophilisats de liposomes |
| CH646390A5 (de) * | 1980-05-12 | 1984-11-30 | Polyfill Ag | Druckdose. |
| DE3207289A1 (de) * | 1982-03-01 | 1983-09-15 | Perfect-Valois Ventil GmbH, 4600 Dortmund | Abgabeventil fuer aerosoldosen |
| EP0100964A3 (de) * | 1982-07-31 | 1984-06-13 | Reifenrath, Rainer, Dr. | Pharmazeutisches Erzeugnis zur Behandlung und Prophylaxe von Infektionen sowie von Husten und obstruktiven Atemwegserkrankungen sowie Verfahren zu seiner Herstellung |
| FR2543018B1 (fr) * | 1983-03-22 | 1985-07-26 | Oreal | Procede de preparation de vesicules lipidiques par vaporisation de solvants |
| CH664943A5 (de) * | 1983-08-16 | 1988-04-15 | Sterwin Ag | Zweikomponentenpackung. |
-
1983
- 1983-08-17 GB GB838322178A patent/GB8322178D0/en active Pending
-
1984
- 1984-08-03 NZ NZ209112A patent/NZ209112A/xx unknown
- 1984-08-06 ZA ZA846064A patent/ZA846064B/xx unknown
- 1984-08-06 IL IL72590A patent/IL72590A/xx unknown
- 1984-08-10 AU AU31786/84A patent/AU569314B2/en not_active Ceased
- 1984-08-14 ES ES535163A patent/ES535163A0/es active Granted
- 1984-08-15 DE DE19843430385 patent/DE3430385A1/de not_active Withdrawn
- 1984-08-15 FI FI843223A patent/FI85214C/fi not_active IP Right Cessation
- 1984-08-16 IE IE2121/84A patent/IE57537B1/en not_active IP Right Cessation
- 1984-08-16 SE SE8404118A patent/SE459471B/sv not_active IP Right Cessation
- 1984-08-16 CH CH395884A patent/CH667384B/xx not_active IP Right Cessation
- 1984-08-16 KR KR1019840004923A patent/KR850001689A/ko not_active Withdrawn
- 1984-08-16 GR GR80127A patent/GR80127B/el unknown
- 1984-08-16 DK DK392884A patent/DK163479C/da not_active IP Right Cessation
- 1984-08-16 NL NL8402514A patent/NL8402514A/nl not_active Application Discontinuation
- 1984-08-16 GB GB08420850A patent/GB2145107B/en not_active Expired
- 1984-08-16 JP JP59170982A patent/JPS6089414A/ja active Pending
- 1984-08-16 AT AT0263684A patent/AT389993B/de not_active IP Right Cessation
- 1984-08-17 PT PT79104A patent/PT79104B/pt not_active IP Right Cessation
- 1984-08-17 IT IT22357/84A patent/IT1175612B/it active
- 1984-08-17 FR FR8412930A patent/FR2550706B1/fr not_active Expired
- 1984-08-17 LU LU85512A patent/LU85512A1/fr unknown
- 1984-08-17 BE BE0/213504A patent/BE900375A/fr not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE459471B (sv) | Liposomal aerosolkomposition samt foerfarande och foerpackning foer framstaellning daerav | |
| Gungor et al. | Nanocarriers mediated topical drug delivery for psoriasis treatment | |
| US5653996A (en) | Method for preparing liposomes | |
| AU587472B2 (en) | Liposome inhalation method and system | |
| TW497974B (en) | High dose liposomal aerosol formulations | |
| EP0607118B1 (en) | A phospholipid delivery system | |
| EP0190926B1 (en) | A method for the preparation of liposomes, a pack for use therein and a composition for use in preparing a liposomal material | |
| KR910004580B1 (ko) | 의약용 소입자 에어로졸 리포좀 및 의약용 리포좀-약제 조합물 | |
| Tomizawa et al. | Uptake of phosphatidylserine liposomes by rat Peyer's patches following intraluminal administration | |
| HU198835B (en) | Process for producing pharmaceutical compositions forming liposomes | |
| JP2005120095A (ja) | 多胞状リポソームへの薬剤封入量の調節 | |
| Ray et al. | Noisomes: as novel vesicular drug delivery system | |
| US5654000A (en) | Pharmaceutical compositions for transmucosal delivery of peptides | |
| US11712407B2 (en) | Hybrid-type multi-lamellar nanostructure of epidermal growth factor and liposome and method for manufacturing same | |
| Kumar et al. | Formulation & Evaluation of Flubriprofen Drug Loaded Liposomes | |
| WO2002089769A2 (de) | Verfahren zum aufbringen eines wirkstoffs auf ein substrat | |
| NO171707B (no) | Fremgangsmaate og forpakning for fremstilling av aerosoler | |
| JP3202705B2 (ja) | 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子 | |
| JP3202704B2 (ja) | 医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子 | |
| Reddy et al. | International Journal of Indigenous Herbs and Drugs | |
| Palekar-Shanbhag et al. | Use of Medicated Foams for Skin Diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8404118-5 Effective date: 19940310 Format of ref document f/p: F |